Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU

Published:2017-04-24 Issue:10 Volume:64 Page:e26555
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Lebovic Rachel¹,Pearce Natalie²,Lacey Laura³,Xenakis James⁴,Faircloth Cassidy B.⁵,Thompson Patrick⁶

Affiliation:

1. Department of Pharmacy Services; University of Michigan Comprehensive Cancer Center; Ann Arbor Michigan

2. UNC at Chapel Hill Eshelman School of Pharmacy/United Therapeutics; Chapel Hill North Carolina

3. Carolinas Healthcare System North East; Charlotte North Carolina

4. Department of Biostatistics and Gillings School of Public Health; University of North Carolina; Chapel Hill North Carolina

5. Department of Pharmacy; University of North Carolina Medical Center; Chapel Hill North Carolina

6. University of North Carolina Lineberger Comprehensive Cancer Center; Chapel Hill North Carolina

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology, and Child Health

Reference14 articles.

1. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report;Linker;Blood,1991

2. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia;Clavell;N Engl J Med,1986

3. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511;Wetzler;Blood,2007

4. How I treat acute lymphoblastic leukemia in older adolescents and young adults;Curran;Blood,2015

5. Frontline treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US Intergroup Trial C10403 (Alliance) [abstract];Advani;Blood,2013

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Asparaginase: Optimizing Efficacy and Minimizing Toxicity in Pediatric and AYA ALL/LBL;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Retrospective review of the toxicities and change in dosing patterns for pegaspargase in patients with acute lymphoblastic leukemia/lymphoma and T-cell lymphoma;Journal of Oncology Pharmacy Practice;2024-04-13

3. Hypoglycemia Associated With PEG-asparaginase and 6-MP Therapy During Treatment of Acute Lymphoblastic Leukemia in Pediatric Patients: A Case Series;Journal of Pediatric Hematology/Oncology;2024-02-27

4. Impact of pegaspargase dose capping on incidence of pegaspargase-related adverse events in adults;Journal of Oncology Pharmacy Practice;2023-09-20

5. Drug-Induced Acute Pancreatitis: An Evidence-Based Classification (Revised);Clinical and Translational Gastroenterology;2023-07-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3